EOD v1.5 known issues:

1/24/2019

  • Corpus Carcinoma and Carcinosarcoma: morphology 8441/2 does not currently allow T1a
  • Prostate: Prostate Pathologic Extension will be renamed to clarify it is part of EOD

EOD v1.5 Review and Conversion:

In the audit log below, a few of the changes impact how a case should be coded. We recommend the following:

  1. If Schema ID [#3800] = 00360 (Lung)
    * If EOD Primary Tumor [#772] = 550, convert to EOD Primary Tumor = 675
    - - - (The value 550 was not reused so this conversion can always be applied.)
  2. If Schema ID [#3800] = 00580 (Prostate)
    * If Prostate Pathological Extension [#3919] = 250, convert to Prostate Pathological Extension = 300
    - - - (The value 250 was not reused so this conversion can always be applied.)
  3. If Schema ID [#3800] = 00740 (Thyroid Medullary)
    When you first deploy version 1.5 if you have existing data, apply the conversion:
    * If EOD Primary Tumor [#772] = 300, convert to EOD Primary Tumor = 400
    * If EOD Primary Tumor = 200, convert to EOD Primary Tumor = 300

    Moving forward, for databases where new records are imported from outside sources (such as a central registry), require a review:
    * If EOD Primary Tumor = 200 or 300, please review
  4. These two combinations must be flagged as needing review. Since the schema changed, the associated SSDIs and valid values for schema specific fields would also change.
    * If primary site = C210 and histology = 8720-8790, please review
    - - - (Schema changed from Melanoma Skin (00470) to Anus (00210))
    * If primary site = C809 and histology = 8041, please review
    - - - (Schema changed from Merkel Cell Skin (00460) to Ill-Defined Other (99999))

EOD v1.5 changes:

While specific schemas note that the schema should be re-calculated with the new algorithm, it may be easier to run all the 2018 and later cases through the algorithms again to ensure all changes to derivations are applied.

EOD and SS2018

includes changes to schema definitions, EOD fields and SS2018

  • Anus: C210 with 8720-8790 was added to this schema; it is not eligible for AJCC staging
  • Colon and Rectum, NET Colon and Rectum
    - - EOD Regional Nodes: In Code 300, for Rectum (C209), 'Iliac (hypogastric, internal, obturator) (see EOD Mets for common, external, NOS)' was added
    - - EOD Mets: for Colon, 'Iliac (common, external, hypogastric, internal, obturator, NOS)' was added (Notes in Colon and Rectum; code 20 in NET Colon and Rectum)
    - - EOD Mets: Rectum and Rectosigmoid were separated (Notes in Colon and Rectum; code 20 in NET Colon and Rectum)
    - - SS2018: Code 3, for Rectum (C209), 'Iliac (hypogastric, internal, obturator) (see code 7 for common, external, NOS)' was added
    - - SS2018: Code 7, for Distant Lymph Nodes, NOS, Rectum and Rectosigmoid were separated
  • Ill-Defined Other: C809 with 8041 was added to this schema
  • Liver: EOD Primary Tumor code 150 changed to contribute an 'RE' to the SS2018 derivation (had been an L)
    • We suggest that 2018-2019 cases in these schemas be re-calculated with the new algorithm, no coding change is necessary
  • Lung
    - - EOD Primary Tumor: '(AIS)' was removed from code 100; Code 550 was changed to be code 675
    - - EOD Regional Nodes: 'Cervical' removed from code 700
    - - SS2018: removed "Chest wall (thoracic wall)" from code 7; added "Brachial Plexus" and "Chest wall (thoracic wall)" to code 2
  • Lymphoma-CLL/SLL: Note 3 changed to state CLL/SLL is always 'staged' as a lymphoma
  • Melanoma Skin
    - - C210 with 8720-8790 was removed from this schema (see Anus)
    - - EOD Regional Nodes: Note 6, for Skin of lower limb and hip, 'Inguinal' was added; Code 300 was revised to be 'WITHOUT involved lymph nodes'
    - - SS2018: Code 3, for Skin of lower limb and hip, 'Inguinal' was added
  • Merkel Cell Skin
    - - C809 with 8041 was removed from this schema (see Ill-Defined Other)
    - - EOD Regional Nodes: Note 4, for Skin of lower limb and hip, 'Inguinal' was added
    - - SS2018: Code 3, for Skin of lower limb and hip, 'Inguinal' was added; 'In-transit metastasis present WITH or WITHOUT lymph node metastasis' was added
  • NET Appendix: EOD Primary Tumor, Subserosa was moved from code 200 to code 100; Serosa was added to code 200
  • Pancreas: EOD Mets code 70 changed to contribute a 'D' to the SS2018 derivation (had been a U)
    • We suggest that 2018-2019 cases in these schemas be re-calculated with the new algorithm, no coding change is necessary
  • Prostate
    - - EOD Primary Tumor: in code 700, Bone was removed from 'Further Contiguous extension'
    - - Prostate Path Extension: in code 700, Bone was removed from 'Further Contiguous extension'
    - - Prostate Pathological Extension: code 250 was incorporated into code 300; code 250 has been removed
  • Skin Other
    - - EOD Regional Nodes: In code 300, for Skin of lower limb and hip, 'Inguinal' was added
    - - SS2018: Code 2 had C000-C002, C006 added to the sites for Head and Neck skin primaries only.
    - - SS2018: Code 3 had the text before the site list changed to Head and Neck skin primaries only. For Skin of lower limb and hip, 'Inguinal' was added
  • Testis
    - - EOD Primary Tumor: PURE SEMINOMAS ONLY that are equal to 3 cm were moved from code 100 to 150
    - - EOD Mets: 'WITH or WITHOUT distant lymph nodes' was added to code 50
    - - SS2018: Code 1 had 'or UNKNOWN if lymphovascular invasion' added
  • Thymus: EOD Primary Tumor code 200 changed to contribute an 'RE' to the SS2018 derivation (had been an L)
  • Thyroid Medullary: In EOD Primary Tumor, a new code 200 was added to match Thyroid EOD Primary Tumor; original code 200 changed to be 300; original code 300 changes to be 400

SSDI and Grade

NAACCR is the custodian of these fields, changes are listed here for convenience. See Change Log on https://apps.naaccr.org/ssdi/list/ for complete information.

  • Bone Appendicular Skeleton, Bone Pelvis, Bone Spine: Post Neoadj Chemo Percent Necrosis [#3908] Note 3 was modified to include no neoadjuvant therapy
  • Breast
    - - Estrogen Receptor Total Allred Score [#3828], Progesterone Receptor Total Allred Score [#3916]: Bullets in Note 3 were modified to refer to Allred Score and provide location of reference table
    - - Multigene Signature Results [#3895]: Note 5 range was changed to 0 - 100
    - - HER2 IHC Summary [#3850], HER2 ISH Summary [#3854], HER2 ISH DP Ratio [#3852], HER2 ISH DP Copy No [#3851], HER2 ISH SP Copy No [#3853] were changed to SEER_REQUIRED = No. These will be RC for SEER in the NAACCR manual (Collected by SEER from CoC accredited hospitals)
  • Cervix, Vagina, Vulva: LN Assessment Method Femoral-Inguinal [#3871], LN Assessment Method Para-Aortic [#3872], LN Assessment Method Pelvic [#3873]: Note 3 was adding detailing what to do when there is no mention of LN involvement for the specified type and Note 4 was modified to reference LN Status Femoral-Inguinal, Para-Aortic, Pelvic [#3884]
  • Colon and Rectum
    - - CEA Pretreatment Lab Value [#3820]: Note 5 about how to code uncertain values was moved to the general instructions
    - - KRAS [#3866]: Note 4 changed to be "Results from nodal or metastatic tissue may be used for KRAS."
    - - Microsatellite Instability (MSI) [#3890]: Note 3 added describing how to code MMR proficient
    - - Perineural Invasion [#3909]: Note 4 added detailing how to code if surgical resection was performed
  • Corpus Adenosarcoma, Corpus Carcinoma and Carcinosarcoma, Corpus Sarcoma: spelling of 'Positive' in Number of 'Postive' Pelvic Nodes [#3902] was corrected
  • Esophagus and Esophagus Squamous
    - - Grade Clin [#3843]: Note 6 about AJCC 8th edition stage group was removed
    - - Grade Post Therapy [#3845]: Note 5 about AJCC 8th edition stage group was removed
  • Melanoma Skin
    - - LDH Pretreatment Lab Value [#3932]: Note 3 was modified to add LDH Pretreatment Level [#3869]
    - - LDH Pretreatment Level [#3869]: Note 4 was added indicating that the same test should be used for multiple data items
    - - LDH Upper Limits of Normal [#3870]: Note 3 was modified to add LDH Pretreatment Lab Value [#3932]
  • Oral Cavity Schemas: NAACCR item [#3883] name was changed to 'LN Size'
  • Plasma Cell Myeloma: High Risk Cytogenetics [#3857], LDH Pretreatment Level [#3869], Serum Albumin Pretreatment Level [#3930], Serum Beta-2 Microglobulin Pretreatment Level [#3932], had a note added that if Schema Discriminator 1 is coded as 1 or 9, the SSDI should be blank
  • Prostate
    - - PSA Lab Value [#3920]: Note 3 instructions on how to handle uncertain values were moved to general instructions
    - - Number of Cores Positive [#3898], Number of Cores Examined [#3897]: Note 3 had sub-bullet added detailing that cores in other areas should not be included
  • Skin Eyelid: Perineural Invasion [#3909], Note 4 added detailing how to code if surgical resection was performed
  • Testis
    - - AFP Pre-Orchiectomy Lab Value [#3807], AFP Pre-Orchiectomy Range [#3808]: Note 4 added detailing conversion for IU/ml
    - - AFP Post-Orchiectomy Lab Value [#3805], AFP Post-Orchiectomy Range [#3806]: Note 5 added detailing conversion for IU/ml
    - - S Category Clinical [#3923]: Note 4 modified to show that S2 also only needs one elevated test
    - - S Category Pathological [#3924]: Note 5 modified to show that S2 also only needs one elevated test